DNDi welcomes the findings of the 2018 G-FINDER report

23 January 2019
Geneva, Switzerland
The annual G-FINDER report provides policy-makers, donors, researchers, and industry with a comprehensive analysis of global investment into R&D of new products to prevent, diagnose, control, or cure neglected diseases in developing countries. It gives an up-to-date analysis of how R&D investments are being allocated across 33 neglected diseases, and product types, funding trends over time, and where the potential gaps lie.

Santa Cruz Letter

15 November 2018
On November 15, 2018, members of the Chagas Clinical Research Platform and the Global Chagas Coalition, participating in the VIII Meeting of the Chagas Platform in Santa Cruz de la Sierra, Bolivia, signed this letter addressed to governments, organizations and donors requesting an intensification in the efforts to control and eliminate Chagas disease as a public health problem. In the last 10 years, there have been significant efforts in the fight against the disease. However, many challenges remain. Next 2019 marks the 110th anniversary since the discovery of the disease and constitutes an opportunity to call attention to people affected by the disease and pursue necessary actions.

DNDi North America submits brief to the Canadian Standing Committee on Health (HESA) Study on Federally Funded Health Research

October 2018
To help inform the Canadian government’s approach to biomedical innovation, particularly as relates to innovations of public health importance, DNDi has submitted a contribution providing concrete evidence of DNDi’s experience implementing needs-driven, open, collaborative R&D. The contribution recommends a series of progressive policy steps Canada can support to re-orient the global biomedical R&D system so that it (1) prioritizes patient and public health needs; (2) is sustainably financed; and (3) incorporates global norms that will enable the discovery, development, and delivery of and equitable access to innovations of public health importance.

DNDi contribution to the World Health Organization roadmap on access to medicines and vaccines 2019-2023

10 September 2018
Geneva, Switzerland
As a contribution to the World Health Organization roadmap on access to medicines and vaccines, Dr Bernard Pécoul noted the importance of including concrete deliverables in the short-, medium-, and long-term, including prioritization of R&D, open and collaborative approaches to innovation, regulatory infrastructure, and solving gaps in diagnostics and specific needs of children.

Fair Pricing Forum 2017

May 10-11, 2017
Amsterdam, The Netherlands
Organized by the World Health Organization in collaboration with the Dutch Ministry of Health, the Fair Pricing Forum was held to discuss options for a fairer pricing system, that is sustainable for both health systems and innovation challenges to access and how to move forward.

DNDi participated in the event.

DNDi response to the Report of the United Nations Secretary-General’s High-Level Panel on Access to Medicines

[14 September, 2016]
The Drugs for Neglected Diseases initiative (DNDi) today welcomes the release of the report of the United Nations Secretary General’s High-Level Panel on Access to Medicines. The Panel has clearly confirmed the policy misalignment between intellectual property and trade rules, international human rights obligations, and public health objectives. It has underlined many immediate access challenges and steps that must be taken to overcome them, and highlighted that existing funding and incentive mechanisms are not adequate to stimulate innovation to address global public health needs.

Ensuring sustained incentives for pharmaceutical companies to develop medicine for the poor

[6 June, 2016]
The Access to Medicine Foundation report explores the progress made by major pharmaceutical companies in collaborating to innovate products for diseases of poverty, and the success of research & development (R&D) models in incentivizing these contributions. For the past 10 years, the Access to Medicine Foundation has tracked the progress of pharmaceutical engagement in R&D for neglected diseases, they found that models like Product Development Partnerships (PDPs) have been highly successful in creating incentives for pharmaceutical companies to participate in access-friendly R&D.

DNDi proposal to UN High-Level Panel on Access to Medicines

[27 February, 2016]
The proposed objective of the UN Secretary General’s High-Level Panel on Access to Medicines is to review and assess proposals and recommend solutions for remedying the policy incoherence between the rights of inventors, international human rights law, trade rules and public health in the context of health technologies. DNDi submitted a formal contribution.

138th session of the WHO Executive Board

[23 February, 2016]
DNDi attended the 138th Executive Board of the World Health Organization. The Executive Board was considering a resolution to add the mycetoma to WHO’s official list of neglected diseases.The mycetoma resolution will be proposed for adoption at the upcoming World Health Assembly agenda in May.

Demonstration Financing: Considerations for a Pilot Pooled International Fund for R&D

[July, 2014]
A new paper recently commissioned by DNDi examines the possibilities of creating a pooled international R&D fund for the Demonstration Projects that were selected as part of the process following on the report of the WHO Consultative Expert Working Group on Research and Development (CEWG): “Demonstration Financing: Considerations for a Pilot Pooled International Fund for R&D.”